Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.45M$11.45Mderived−7.5% vs Q4 2016 Net Income-$511.21K-$511.21KderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,040,166+1,064.1% Operating Incomederived-$3,886,421N/M Operating Cash Flowderived-$941,223N/M Margins · derivedGross margin17.8%+16.4 pt vs Q4 2016
Operating margin-33.9%−16.4 pt vs Q4 2016
Net margin-4.5%−15.0 pt vs Q4 2016
ended Dec 31, 2017 · filed Apr 2, 2018 · 92 d after period end